Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World October 19, 2015 Philippa Matthews	BMS agrees $1.7bn immuno-oncology collaboration Bristol-Myers Squibb has entered into a worldwide license and collaboration with Five Prime Therapeutics to develop and commercialize Five Prime's colony stimulating factor 1 receptor (CSF1R) antibodies.
Chemistry World August 5, 2015 Rebecca Trager	Grabbing slices of the immuno-oncology pie An increasing number of companies are competing for a slice of the immuno-oncology market
Chemistry World July 8, 2014 Phillip Broadwith	First of a new breed of anticancer antibodies approved in Japan Ono pharmaceuticals' Opdivo (nivolumab) has been approved for treating melanomas where surgery is impossible.
Chemistry World June 12, 2014 Andy Extance	Pharma vies to unleash immune system power on cancer Drug firms are investing heavily in clinical trials and collaborations as they seek to capitalize on the potential of cancer therapies that enlist or enhance our immune systems' ability to fight tumors.
Chemistry World July 3, 2015 Andy Extance	Pharma queues up for checkpoint inhibitor collaborations Amid fierce rivalries over the latest generation of cancer treatments, drug makers have been weaving a complex web of collaborations on combination therapies spanning much of the pharmaceutical industry.
Chemistry World August 27, 2014 Phillip Broadwith	Clinical collaborations drive cancer immunotherapy A joint clinical trial agreement between Merck & Co and Pfizer is the latest in a rather tangled web of tie-ups between companies with cancer drugs that harness patients' immune systems.
The Motley Fool February 23, 2011 Brian Orelli	Gilead Gears Up to Fight Cancer Gilead has been infected by the diversification bug.
BusinessWeek June 16, 2011 Langreth & Cortez	When Two Cancer Drugs Are Better Than One Drugmakers are collaborating to test combinations of genetically targeted cancer drugs in hopes of boosting survival rates.
The Motley Fool June 29, 2011 Brian Orelli	Doubling Up in Biotech Lilly hits multiple targets with one drug.
The Motley Fool May 10, 2005 Charly Travers	The Future of Cancer Therapy Biotech firm Exelixis is blazing a trail for long-term success. Should investors take notice?
The Motley Fool December 20, 2011 Luke Timmerman	Amgen, Watson Strike $400M Deal for Biosimilar Cancer Drugs What does this important collaboration mean for biosimilars?
The Motley Fool December 5, 2005 W.D. Crotty	Rigel Pharmaceuticals Gets Stomped The biotech tumbles on poor phase 2 trial results for an allergy drug. Until another compound begins to offer glimmers of hope, this stock will probably offer little if any price appreciation.
The Motley Fool November 18, 2004 Charly Travers	A Glimpse of Bristol-Myers' Portfolio Late-stage drugs are crucial for a company beset with patent losses.
The Motley Fool March 2, 2010 Brian Orelli	Merck: Poised for Growth and Eager to Go Merck needs its new, stronger, post-acquisition pipeline to pay off.
The Motley Fool January 25, 2006 Stephen D. Simpson	Bristol-Myers Catches a Cold Tough days are coming, but so are promising new drugs. It's understandable why long-term investors might be willing to hold on and see how things work out.
The Motley Fool December 20, 2007 Brian Orelli	2007: The Year Pharma Fell in Love With Biologics The reason for pharma's newfound infatuation for biotech is quite clear. Many pharmaceutical companies are facing a patent cliff in the coming years, and they need to replace their blockbusters with something.
The Motley Fool July 24, 2009 Brian Orelli	Bristol-Myers: Eat or Be Eaten Bristol-Myers Squibb, the oft-rumored acquisition target of partner sanofi-aventis, is doing a little acquiring of its own, which might settle down the rumor mill.
Managed Care May 2004	Biologics Among Fastest Growers Managed care plans and pharmacy benefit managers can benefit from the strong generic presence in the market, but also face challenges relating to biotech drugs.
The Motley Fool June 25, 2010 Brian Orelli	Diversification Times 50,000 Gilead Sciences diversifies any way it can.
The Motley Fool April 29, 2008 Brian Lawler	Medarex Takes Another Hit Its lead cancer-fighting drug suffers a regulatory delay.
The Motley Fool April 28, 2008 Brian Lawler	Bristol-Myers' Comeback Continues The pharmaceutical's first quarter brings more robust results.
The Motley Fool November 1, 2004 Brian Gorman	Bristol-Myers Stays the Course The pharma remains downbeat on its outlook through 2006, but two promising compounds could lift the company's fortunes.
The Motley Fool October 2, 2007 Billy Fisher	Closure for Bristol-Myers Bristol-Myers will pay $515 million to resolve cases from state and federal authorities alleging that the company promoted products for uses that hadn't been approved by the FDA.
Chemistry World September 2010	Column: In the pipeline Derek Lowe considers the quandaries of living in the age of the kinase
The Motley Fool October 26, 2010 Brian Orelli	Where's the Growth in Big Pharma? The theme for the pharmaceutical industry's 2010 third-quarter earnings reports has been officially set: If you can't get it done through sales, just cut costs.
The Motley Fool January 26, 2005 Stephen D. Simpson	The Pipeline to Biotech Success Looking at drug R&D is the best way to begin assessing biotech companies as possible investment opportunities.
Chemistry World December 2009	Column: In the pipeline Is the pharmaceutical industry churning out copycat versions of existing therapies? The author dispels a few myths about 'me-too' drugs
The Motley Fool March 14, 2008 Brian Orelli	Weighing In on Obesity Drugs Could investing in drugmakers that produce weight-loss drugs help fatten your wallet?
The Motley Fool December 10, 2008 Brian Orelli	Merck: Same Plan, With a Twist With increasing generic competition and languishing sales of cholesterol-lowering drugs Vytorin and Zetia, Merck is doing its best to replace sales by pushing new drugs through its pipeline.
The Motley Fool January 28, 2011 Luke Timmerman	Merck, Staring at a Biotech Future, Seeks to Get in the Game With New Protein Drugs, Biosimilars Biotech drugs will soon dominate the pharmaceutical industry, and Merck is playing catch-up.
The Motley Fool October 1, 2008 Brian Orelli	3 Drugmakers With Multiple Shots on Goal Well-stocked pipelines could kick these drugmakers into super-high gear.
The Motley Fool July 18, 2005 Karl Thiel	Stocks That Make You Breathe Easier Allergies and asthma are big markets that several firms aim to tackle. Investors, take note.
The Motley Fool July 14, 2005 Stephen D. Simpson	Dueling Fools: Protein Design Labs Bear Protein Design Labs could be a big winner, or a major loser. The biotech has a strong business, but today's stock price isn't "great."
The Motley Fool November 27, 2009 Brian Orelli	Biotech Bargains for Your Portfolio Everyone is looking for bargains this time of year. That includes pharmaceutical giants looking to pick up some biotechs on the discount rack, and investors trying to get there first.
The Motley Fool July 28, 2005 Stephen D. Simpson	Bristol-Myers' Road to Better Health Bristol-Myers looks toward 2007 and a resumption of real growth. For now, things could be a lot worse. At least investors can't say they're not getting paid to be patient.
The Motley Fool September 12, 2005 M.D. Mitchell	Big Problems for Big Pharma Creating new drugs is never easy, but the companies that excel in three key areas are the ones for investors to watch.
The Motley Fool June 26, 2009 Brian Orelli	The $16 Billion Market That Could Make You Rich A large market just waiting to be taken over.
The Motley Fool January 29, 2010 Brian Orelli	All Grown Up, With Cash to Burn Bristol-Myers is all drugs, all the time.
The Motley Fool October 26, 2011 Selena Maranjian	Make Money in Promising Biotech Stocks the Easy Way If you expect the biotech industry to thrive as scientists develop more drugs to treat our aging population, the iShares Nasdaq Biotechnology ETF could be for you.
The Motley Fool September 17, 2008 Brian Orelli	IPO? In This Market? Bristol-Myers continues with plans to spin off its nutritionals business.
The Motley Fool January 28, 2011 Brian Orelli	Looking Ahead at Bristol-Myers Product approvals now will help with the upcoming patent cliff.
The Motley Fool February 27, 2009 Brian Orelli	Can $634 Billion Save the U.S. Health Care System? The good news is that Obama's budget includes a $634 billion down payment on getting insurance for the 48 million uninsured. The bad news is that the president has to pay for that by cutting costs in other areas.
The Motley Fool January 12, 2011 Brian Orelli	Drugmaker Math: 4 Halves Beat 2 Wholes Eli Lilly and Boehringer Ingelheim hook up.
The Motley Fool October 9, 2006 Brian Lawler	The Commandments of Biotech Investing, Part 2 It's a complex field, but it's not impossible for investors to master. The more in-depth your research of a potential biotech investment, and the more you remember to follow these commandments, the better your potential for success will be when investing in this fascinating field.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool February 17, 2010 Brian Orelli	$1.24 Billion Deal. Shares Fall 9%. That Makes Sense. Rigel Pharmaceuticals signed up AstraZeneca to take over development of its phase 2 rheumatoid arthritis drug, R788, with more than $1.24 billion in potential payments, and the shares fell more than 9%.
The Motley Fool March 3, 2009 Brian Orelli	Stop Worrying About Follow-On Biologics They're inevitable, but they won't hurt biotech as much as you might think.
The Motley Fool January 8, 2008 Brian Orelli	Brits May Bludgeon Drug Companies The U.K.'s National Health Service delivers a shock to drugmakers; it is considering a 10% drop in the rate that it pays for drugs, to help it reach its goal of a 3% reduction in the nation's overall health-care bill.
The Motley Fool August 17, 2004 Charly Travers	Surviving Biotech's Downturns Advice on withstanding the volatility of the biotech sector.
The Motley Fool December 16, 2003 David Nierengarten	Biotech's Next Phase It's been a great year for biotech, but don't count on a repeat in 2004. Here are some tips for evaluating biotechnology and pharmaceutical stocks.